Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL

NCT02758665 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Lymphocytic, Chronic

Interventions

DRUG: ibrutinib
DRUG: obinutuzumab
DRUG: venetoclax

Sponsor

University of Ulm

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]